Piper Jaffray is providing a “positive update” on Overweight-rated Gen-Probe Inc. (NASDAQ: GPRO) following its meetings with management.

“Although early in the EU panther launch, management appeared pleased with adoption thus far,” Piper Jaffray writes. “On the menu side, we believe Trich could garner near term approval and we remain positive on this assay.

“Separately, 2013 appears reasonable for a U.S. viral load introduction, suggesting Gen-Probe already has a solid internal assay(s) and lastly, PCA-3 appears close to a panel meeting announcement, although we remain skeptical about the longer term potential here.”

Gen-Probe closed Tuesday at $63.22.